Psychedelic
Medicine

Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms. When ingested, it converts to psilocin, which activates serotonin receptors in the brain, particularly the 5-HT2A receptor. This leads to altered perception, enhanced emotional processing, and increased neuroplasticity. Research shows psilocybin creates rapid and durable antidepressant effects, with single doses producing symptom reductions lasting weeks to months. Compass Pathways' COMP360, a synthetic psilocybin formulation, successfully met primary endpoints in two Phase 3 trials for treatment-resistant depression in 2026, showing a 3.8-point MADRS reduction compared to control doses. The compound appears to work by disrupting rigid thought patterns and promoting cognitive flexibility, while simultaneously reducing activity in the brain's default mode network, which is often hyperactive in depression. Johns Hopkins, Imperial College London, and other leading institutions have published groundbreaking studies demonstrating psilocybin's efficacy for depression, anxiety in cancer patients, addiction, and obsessive-compulsive disorder. The therapeutic effects appear enhanced when combined with psychotherapy and intention-setting.

Ketamine is a dissociative anesthetic that acts primarily as an NMDA receptor antagonist, producing rapid antidepressant effects through glutamate modulation and enhanced BDNF (brain-derived neurotrophic factor) production. Unlike classical psychedelics that work on serotonin receptors, ketamine's glutamate pathway allows it to work in patients taking SSRIs and produces effects within hours rather than weeks. Esketamine (Spravato), the S-enantiomer of ketamine, received FDA approval in 2019 for treatment-resistant depression when used with oral antidepressants, and in January 2025 gained approval as a monotherapy. Clinical studies show esketamine produces rapid improvement in depressive symptoms as early as 24 hours, with 22.5% achieving remission versus 7.6% on placebo. Ketamine clinics have proliferated across the United States, offering IV infusions, intramuscular injections, nasal spray, and lozenges for depression, anxiety, PTSD, and chronic pain. At-home ketamine services like Mindbloom and Nue Life have expanded access through telemedicine, with 35+ states now served. The ketamine experience at sub-anesthetic doses involves dissociation, altered time perception, and dreamlike states lasting 45-90 minutes. Research suggests ketamine's antidepressant effects stem from rapid synaptogenesis in the prefrontal cortex, essentially rebuilding neural connections weakened by chronic stress and depression.

MDMA is a synthetic empathogen-entactogen that increases release and blocks reuptake of serotonin, dopamine, and norepinephrine. Unlike classical psychedelics, MDMA primarily enhances feelings of emotional closeness, empathy, and reduces fear responses without typically causing hallucinations. This unique pharmacological profile makes it particularly effective for trauma processing, as it allows patients to revisit traumatic memories without overwhelming fear or defensive reactions. MAPS (Multidisciplinary Association for Psychedelic Studies) conducted extensive Phase 3 trials showing MDMA-assisted therapy significantly reduced PTSD symptoms, with 67% of participants no longer meeting PTSD diagnostic criteria after treatment. However, the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics, citing concerns about study design, functional unblinding (94% of participants correctly identified receiving MDMA vs placebo), and lack of active comparators. The FDA requested an additional Phase 3 study before reconsideration. Despite this setback, MDMA remains one of the most promising psychedelic medicines, with Australia approving limited psychiatric use in 2023 and Utah launching a pilot program in 2024. The therapeutic mechanism appears to involve temporary reduction in amygdala hyperactivity while increasing prefrontal cortex connectivity, allowing for fear memory reconsolidation.

Ayahuasca is a traditional Amazonian plant brew combining the Banisteriopsis caapi vine (containing MAO inhibitors) with Psychotria viridis leaves (containing DMT). The MAO inhibitors allow the orally inactive DMT to become psychoactive, creating a profound 4-6 hour visionary experience. Indigenous peoples of the Amazon have used ayahuasca for thousands of years in shamanic healing ceremonies for physical ailments, emotional distress, spiritual guidance, and treating addiction. Modern research shows ayahuasca promotes neuroplasticity through sigma-1 receptor activation at mitochondria-associated membranes, reducing inflammation, oxidative stress, and cellular stress responses. Clinical studies demonstrate rapid antidepressant effects, with single doses reducing HAM-D and MADRS scores significantly for up to 21 days. The brew's beta-carboline alkaloids (harmine, harmaline, tetrahydroharmine) contribute additional anthelmintic, antimicrobial, vasorelaxant, and neuroprotective properties. Ayahuasca shows particular promise for substance dependence, acting on mesolimbic dopaminergic and serotonergic pathways to break addiction cues and attenuate withdrawal symptoms. The experience typically involves purging (vomiting, diarrhea), which is considered part of the healing process. Emerging research suggests potential for neurodegenerative conditions like Parkinson's, Alzheimer's, and ALS.

Cannabis contains over 100 cannabinoids, with THC (tetrahydrocannabinol) and CBD (cannabidiol) being the most studied. Unlike classical psychedelics, cannabis works through the endocannabinoid system rather than serotonin receptors. THC produces euphoria, relaxation, altered perception, and appetite stimulation, while CBD is non-intoxicating and provides anxiolytic, anti-inflammatory, and neuroprotective effects. Medical cannabis is FDA-approved for specific conditions (Epidiolex for epilepsy, Marinol/Cesamet for chemotherapy nausea), and 38+ U.S. states plus D.C. have medical cannabis programs. Cannabis shows efficacy for chronic pain, nausea, muscle spasticity in MS, sleep disorders, PTSD, anxiety, and appetite stimulation in cancer and HIV/AIDS patients. The plant has been used medicinally for thousands of years across multiple cultures. Modern research explores various ratios of THC:CBD for different conditions, with lower THC/higher CBD ratios preferred for anxiety and inflammation, while balanced or THC-dominant strains help pain and sleep. Risks include potential for psychological dependence, cognitive impairment with heavy use, anxiety/paranoia in susceptible individuals, and respiratory issues with smoking. Cannabis interacts with many medications and should be used cautiously with medical supervision.

DMT (N,N-Dimethyltryptamine) and its close relative 5-MeO-DMT are among the most potent psychedelics known, producing intense but brief experiences. N,N-DMT, found in many plants and the active component of ayahuasca, creates vivid geometric patterns, encounters with seemingly autonomous entities, and profound shifts in consciousness lasting 15-30 minutes when smoked or vaporized. 5-MeO-DMT, found naturally in certain plants and the venom of the Sonoran Desert toad (Incilius alvarius), produces a more unified, often ineffable "white light" experience characterized by ego dissolution and feelings of cosmic unity. Clinical research on 5-MeO-DMT has accelerated dramatically, with multiple Phase 1/2 trials active in 2024-2025. Beckley Psytech's Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression showed rapid, durable antidepressant effects with MADRS reductions of 10.8-11.1 points at day 8, generally well-tolerated with no serious adverse events. Sublingual formulations are also in trials for anxiety and depression. Imperial College London reported that a single dose of ayahuasca's DMT compound produced significant and lasting depression relief in 2026 research. The rapid onset and short duration make DMT particularly interesting for clinical settings, as the entire experience can occur within a supervised session.

LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first synthesized by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors, producing profound alterations in consciousness, perception, mood, and cognition lasting 8-12 hours. During the 1950s-60s, LSD showed remarkable promise in psychiatric research for treating alcoholism, anxiety, and enhancing psychotherapy before political backlash led to prohibition. Modern neuroscience reveals LSD increases brain network connectivity, particularly between regions that don't normally communicate, promoting cognitive flexibility and creative problem-solving. Unlike psilocybin, LSD has a longer duration and tends toward more geometric and abstract visual experiences. Recent clinical trials on LSD microdosing (10-20 μg doses, sub-perceptual) show it is safe in outpatient settings but lacks proven efficacy beyond placebo for core ADHD symptoms in a 2025 phase 2A trial. However, ongoing research explores LSD's potential for anxiety, depression, and cluster headaches. The compound's ability to induce ego dissolution and mystical experiences correlates with therapeutic benefits. Imperial College London pioneered modern LSD neuroimaging, revealing how it temporarily dissolves the brain's default mode network, allowing for psychological flexibility and new perspectives on entrenched problems.

Bufo alvarius (now Incilius alvarius), the Sonoran Desert toad, produces venom containing high concentrations of 5-MeO-DMT, one of the most potent psychedelics known. Despite widespread belief in traditional indigenous use, there is no verified evidence of ceremonial toad venom consumption by indigenous peoples. The Yaqui of the Sonoran Desert considered the toad culturally significant in art and stories but explicitly deny historical ingestion of its venom as psychoactive. Archaeological evidence suggests Mesoamerican awareness of psychoactive toads, but not confirmed ceremonial use. Modern "Bufo ceremonies" emerged around 2015 as neo-shamanic practices, often held at retreats in Tulum, Riviera Maya, Sonora, Oaxaca (Mexico), and Peru's Sacred Valley. The dried venom is vaporized and smoked, producing an extremely intense 15-45 minute experience of ego dissolution, unity consciousness, white light, and often profound healing or trauma release. The toad naturally secretes venom from glands when threatened; this is collected, dried, and stored. Rising global demand for Bufo ceremonies has created serious conservation concerns, with wild toad populations under pressure from over-harvesting. Synthetic 5-MeO-DMT offers an identical experience without harming toads and is increasingly preferred by ethical practitioners. The experience is considered one of the most powerful and potentially transformative in psychedelic medicine, but also carries risks of overwhelming psychological intensity.

Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central West Africa. The Bwiti tradition of Gabon has used iboga in spiritual initiation ceremonies for centuries. Ibogaine is unique among psychedelics for its remarkable ability to interrupt addiction, particularly to opioids, with a single treatment often eliminating acute withdrawal symptoms for weeks and reducing cravings for months. The mechanism involves resetting multiple neurotransmitter systems, including dopamine, serotonin, and opioid receptors, while promoting neuroplasticity and allowing psychological processing of addiction's root causes. A typical ibogaine experience lasts 8-12 hours and involves a waking dream state with intense introspection, life review, and often vivid visions addressing the psychological origins of addiction. Studies show up to 88% reduction in PTSD symptoms post-treatment. However, ibogaine carries significant cardiac risks, including QT interval prolongation and potential fatal arrhythmias, necessitating rigorous medical screening and monitoring. Treatment centers in Mexico (Tijuana, Cancun, Playa del Carmen) and Portugal provide medically supervised protocols with cardiac monitoring, pre-treatment screening, and integration support. Texas approved $50 million in 2025 for clinical trials investigating ibogaine for addiction and brain trauma, signaling growing legitimacy.

San Pedro (Echinopsis pachanoi), known as Huachuma in indigenous traditions, is a mescaline-containing cactus native to the Andes mountains of Peru, Bolivia, Ecuador, and surrounding regions. With over 4,000 years of ceremonial use, it is one of the oldest entheogens in the Americas, predating psilocybin mushroom use. Archaeological evidence from Peru's Chavín culture (1500 BCE) shows stone carvings of shamans holding the cactus. The Inca used San Pedro in ceremonies at Cusco, Machu Picchu, and the Sacred Valley for spiritual communion with deities, purification, divination, healing, and governance counsel. The primary psychoactive compound, mescaline, increases prefrontal cortex activity for emotional regulation and planning while producing heart-opening, empathogenic effects alongside visual enhancements. Traditional curanderos (healers) in Peru and Ecuador use San Pedro tea in blended indigenous-modern medicine for shamanic healing, enhancing perception, awakening intuition, and diagnosing mind-body-spirit imbalances. The experience, lasting 10-14 hours, typically brings euphoria, compassion, empathy, enhanced environmental awareness, and insights into personal problems. Research supports traditional claims of blood pressure reduction, anti-inflammatory effects, and benefits for depression, anxiety, PTSD, and addiction recovery through serotonin and dopamine activation.

Peyote (Lophophora williamsii) is a small, spineless cactus containing mescaline as its primary psychoactive alkaloid. Sacred to the Native American Church (NAC), which has over 400,000 members across 50+ tribes, peyote serves as a holy sacrament in all-night ceremonies for spiritual communion, healing, and addressing personal and social imbalances. The NAC originated around 1885 among Kiowa and Comanche tribes, blending indigenous spirituality with Christian elements to preserve peyote traditions during persecution. Ceremonies occur in tipis around a crescent-shaped altar and sacred fire, running from Saturday evening through Sunday morning. Participants consume peyote (never smoked, only eaten dry, ground, or as tea) with prayer, singing, and contemplation, seeking guidance, healing, and communion with God and spirits. The Peyote Spirit is considered a deity providing visions, promoting brotherly love, family care, steady work, and abstinence from alcohol. Traditional medicine men view peyote as safe for all ages, including children and pregnant women in ceremonial contexts. Beyond spiritual use, peyote's 60+ alkaloids show analgesic and antibiotic properties, with documented benefits for addiction recovery through NAC meetings. The experience typically lasts 10-12 hours with enhanced perception, emotional openness, and spiritual insight.

Rapé (pronounced "ha-peh") is a sacred shamanic snuff made from powdered mapacho (a potent Amazonian tobacco containing high nicotine) blended with ashes from medicinal plants, tree barks, and other botanicals. Indigenous tribes throughout the Brazilian, Colombian, and Peruvian Amazon, including the Huni Kuin, Yawanawa, Katukina, Nukini, and Kaxinawá, have used rapé for centuries in social, ceremonial, and healing contexts. The snuff is traditionally administered using a pipe called a tepi, where one person forcefully blows the powder into another person's nostrils, or with a kuripe for self-administration. The immediate effects include a powerful jolt of stimulation, intense focus, grounding, sinus clearing, and often purging (tears, mucus, vomiting, or defecation). Rapé serves multiple ceremonial functions: cleansing participants before ayahuasca ceremonies, initiating purging during ceremonies, marking the end of ceremonies to cement healing, and as standalone practice for meditation, prayer, and energetic clearing. Each tribe prepares distinct rapé blends with specific purposes, such as grounding, protection from negative energies, emotional release, or enhancing other plant medicines. The nicotine and plant alkaloids provide immediate stimulation followed by calm focus that can last hours. Some blends contain coumarin from Cumaru tree ash, which can be hepatotoxic in large amounts. No Western scientific studies exist on rapé's specific therapeutic properties, though mapacho's nicotine provides known analgesic and cognitive effects.

Kambo is the skin secretion of the giant monkey frog (Phyllomedusa bicolor), native to the Amazon rainforest. Indigenous tribes such as the Matses, Mayoruna, and Katukina have used kambo for centuries to boost physical strength, improve hunting success, ward off bad luck (panema), and induce deep physical and spiritual cleansing. The secretion is collected non-lethally by gently stressing the frog and harvesting the white foam from its skin, then drying it on wooden sticks for storage. Application involves creating small superficial burns on the skin (usually arms, legs, or chest) and applying the kambo dots directly to these points. The experience is immediate and intense, causing rapid heart rate, nausea, vomiting, diarrhea, facial swelling, and a sensation of heat rushing through the body, typically resolving within 30-60 minutes. Kambo contains bioactive peptides including dermorphin and deltorphin (opioid receptor agonists with analgesic effects) and cerulein (stimulates gallbladder and intestinal contractions). Advocates claim benefits for chronic pain, depression, anxiety, autoimmune conditions, and addiction, though clinical evidence remains limited. The purging is considered essential for clearing toxins and negative energy. However, serious adverse events including sudden death and hepatitis have been reported, and medical authorities warn against use due to lack of proven safety or efficacy.